Scale + Churn = Revenue Growth

When it comes to the real estate market the most important factor is location. When it comes to the insulin pump market it’s all about scale. And scale is something Medtronic has in abundance. However, this huge scale is also somewhat misleading, and the results released by Medtronic this morning are a perfect example of just how misleading scale can be.

This morning the company reported “Diabetes Group worldwide second quarter revenue of $583 million increased 26.2 percent, or 27.5 percent on a constant currency basis.” At first glance this seems like very impressive growth yet . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

© 2005 - 2020 Diabetic Investor, Inc., all rights reserved. Unless expressly permitted under your written license agreement, you are not authorized to forward or to otherwise copy our newsletter, or any portion thereof, by electronic means or otherwise. 17 U.S.C. §504 provides for statutory damages of up to $150,000 per infringement of a copyright and additional damages.